MMP2 and nasopharyngeal carcinoma: In nasopharyngeal cancer, FBLN2 inhibits the metastatic properties via downregulation of vascular endothelial growth factor (VEGF) and matrix metalloproteinase 2 (MMP2), one of the ECM associated enzymes [15].